Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification-Reference-Cited by-同舟云学术

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification

Published:2018-10-11 Issue:11 Volume:7 Page:5843-5858
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Muto Reiji¹²^ORCID,Miyoshi Hiroaki¹,Sato Kensaku¹,Furuta Takuya¹,Muta Hiroko¹,Kawamoto Keisuke³,Yanagida Eriko¹,Yamada Kyohei¹,Ohshima Koichi¹

Affiliation:

1. Department of Pathology; Kurume University School of Medicine; Kurume Japan

2. Department of Pathology, National Hospital Organization; Kumamoto Medical Center; Kumamoto Japan

3. Faculty of Medicine, Hematology, Endocrinology, and Metabolism; Niigata University Niigata; Niigata Japan

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1805/fullpdf

Reference27 articles.

1. The incidence of non-Hodgkin’s lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants;Herrinton;Cancer Causes Control,1996

2. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtype differ by geographic location;Anderson;Non-Hodgkin's Lymphoma Classification Project. Ann Oncol,1998

3. Incidence and spectrum of non-Hodgkin lymphoma in Chinese migrants to British Colombia;Au;Br J Haematol,2005

4. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001;Morton;Blood,2006

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial;Future Oncology;2024-06-05

2. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study;Nature Medicine;2024-06-03

3. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

4. Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan;International Journal of Hematology;2024-03-23

5. Incidence trends for common subtypes of T-cell lymphoma in Taiwan and the United States from 2008–2020;International Journal of Hematology;2024-03-17